| |
|
Production Facility @ Naprod Life Sciences |
| |
| In our quest to be a leading
manufacturer in the pharmaceutical industry and a CRAMS player
of global standing; we aspire to meet and excel the highest
industry standards. To this end, on the manufacturing front,
we have designed and engineered our production facilities to
the most rigorous benchmarks. We have a modern facility for
the production of sterile powder formulations, liquid &
lyophilized injection, non-sterile oral formulations and
active pharmaceutical ingredients. |
| |
| Some other features of our
facility: |
| |
- Modern QA, QC, Microbiological and PD Lab supported with
high-tech equipment.
- Fully automated with electronically controlled operating
system as per GAMP-4 (Good Automated Manufacturing Practice)
guidelines.
- Sophisticated Effluent Treatment Plant (ETP) with a
capacity of 100,000 litres per day.
- Conforms to international environmental, health & safety
regulations
|
| |
| Our facility consistently meets
and exceeds our own stringent quality assurance standards,
administered by an Internal Quality Assurance team reporting
directly to the Managing Director, as well as those imposed by
regulatory bodies. IQ /OQ / PQ validations have been completed
on all equipment to which these apply. |
| |
| In addition, we are a registered
drug manufacturing facility with an impressive inspection
record. All our manufacturing sites are WHO-GMP approved.
Further, we are commissioning in December 2008 our new
state-of-the-art manufacturing facilities. These will comply
with the requirements of: |
| |
- USFDA
- INVISA
- INVIMA
- UKMHRA
- TGA-Australia
|
| |
| Our expertise in lyophilization
and in APIs (CTD & formulation dossiers) will help us further
enhance our own product range as well as the size and
diversity of our toll / contract manufacturing business
segment. |
| |
Our current drug delivery
formats include sterile powder formulations, liquid,
lyophilized injection, non-sterile oral formulations and
active pharmaceutical ingredients.
Our product range is categorized as follows: |
| |
- Anticancer Formulations (over 50 products)
- General Formulations (over 20 products)
- API Products (over 40 products)
|
| |
|
The following fact sheets capture the broad contours of our
manufacturing capabilities per Annum: |
| |
 |
Tablets |
|
35 Million |
| |
|
|
|
|
|
Capsules |
|
21 Million |
| |
|
|
|
|
|
Injections |
|
23 Million |
| |
|
|
|
|
| |
